Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours

Capodanno,Alessandra; Boldrini,Laura; Alì,Greta; Pelliccioni,Serena; Mussi,Alfredo; Fontanini,Gabriella

doi:10.3892/or.2012.2017

Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours

Authors:
- Alessandra Capodanno
- Laura Boldrini
- Greta Alì
- Serena Pelliccioni
- Alfredo Mussi
- Gabriella Fontanini
View Affiliations

Affiliations: Department of Surgery, Division of Pathological Anatomy, University of Pisa, I-56124 Pisa, Italy, Department of Cardio-Thoracic Surgery, Division of Thoracic Surgery, University of Pisa, I-56124 Pisa, Italy
Published online on: September 4, 2012 https://doi.org/10.3892/or.2012.2017
Pages: 1559-1566
Copyright: © Capodanno et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bronchopulmonary neuroendocrine tumours (BP-NETs) comprise a large spectrum of tumours including typical carcinoids (TCs), atypical carcinoids (ACs), large-cell neuroendocrine carcinomas (LCNECs) and small-cell lung carcinomas (SCLCs) that exhibit considerably different biological aggressiveness and clinical behaviours. The phosphatidylinositol-3-kinase α catalytic subunit (PIK3CA) gene is known to be involved in the pathogenesis of several types of human cancers through gene amplification, deletions or somatic missense mutations within the helical and catalytic domains. However, the PIK3CA gene status in BP-NETs has yet to be explored. This study aimed to investigate the PIK3CA gene status in a large series of BP-NETs by direct gene sequencing and to analyse its correlation with the main clinicopathological parameters. To the best of our knowledge, we demonstrated for the first time a high frequency of somatic missense mutations (23.2%) in the PIK3CA gene in a series of 190 BP-NETs, including 75 TCs, 23 ACs, 17 LCNECs and 75 SCLCs. The frequency of the PIK3CA gene mutation in the kinase domain was higher (17.9%) than that in the helical domain (5.3%). When the mutational status of the PIK3CA gene was compared with the main clinical and pathological characteristics of the BP-NET patients, we found a significant association between PIK3CA gene mutations and BP-NET histology (p=0.011). Interestingly, the frequency of PIK3CA gene mutations increased with the biological aggressiveness of all BP-NETs, except LCNECs. In conclusion, our results suggest that PIK3CA gene mutations may play a key role in tumourigenesis and aggressiveness of BP-NETs. The PIK3CA gene may represent a favourable candidate for an effective therapeutic strategy in the treatment of patients with BP-NETs.

View Figures

View References

1	Travis WD, Brambilla E, Muller-Hermelink HD and Harris CC: World Health Organization classification of tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Hearth. IARC Press; Lyon: 2004
2	Righi L, Volante M, Rapa I, Scagliotti GV and Papotti M: Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch. 451:S51–S59. 2007. View Article : Google Scholar : PubMed/NCBI
3	Gustafsson BI, Kidd M, Chan A, Malfertheiner MV and Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer. 113:5–21. 2008. View Article : Google Scholar : PubMed/NCBI
4	Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA and Miller JI: The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest. 119:14–18. 2001. View Article : Google Scholar : PubMed/NCBI
5	Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, Yokose T, Jiang SX, Inoue T, Nakagawa K, Tajima K and Nagai K: Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 24:70–76. 2006. View Article : Google Scholar : PubMed/NCBI
6	García-Yuste M, Matilla JM and González-Aragoneses F: Neuroendocrine tumors of the lung. Curr Opin Oncol. 20:148–154. 2008.
7	Srirajaskanthan R, Toumpanakis C, Karpathakis A, Marelli L, Quigley AM, Dusmet M, Meyer T and Caplin ME: Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer. 65:68–73. 2009. View Article : Google Scholar
8	Katso R, Okkenhaug K, Ahamdi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
9	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
10	Vivanco I and Sawyers CL: The phosphatidylinositol-3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
11	Fresno Vara JA, Casado E, De Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
12	Samuels Y, Wang ZH, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell DM, Riggins GJ, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
13	Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, et al: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 3:772–775. 2004. View Article : Google Scholar : PubMed/NCBI
14	Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar : PubMed/NCBI
15	Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 5:921–929. 2005. View Article : Google Scholar : PubMed/NCBI
16	Karakas B, Bachman KE and Park BH: Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
17	Huang CH, Mandelker D, Gabelli SB and Amzel LM: Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle. 7:1151–1156. 2008. View Article : Google Scholar : PubMed/NCBI
18	Maekawa T, Ashihara E and Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 12:327–340. 2007. View Article : Google Scholar : PubMed/NCBI
19	Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
20	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
21	Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
22	Wang L, Ignat A and Axiotis CA: Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol. 10:139–146. 2002. View Article : Google Scholar
23	Yao JC: Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 21:163–172. 2007. View Article : Google Scholar : PubMed/NCBI
24	Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G and Papotti M: Mammalian target of rapamycin signalling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer. 17:977–987. 2010. View Article : Google Scholar : PubMed/NCBI
25	Alì G, Boldrini L, Capodanno A, Pelliccioni S, Servadio A, Crisman G, Picchi A, Davini F, Mussi A and Fontanini G: Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med. 2:787–792. 2011.PubMed/NCBI
26	Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB and Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
27	Li VSW, Wong CW, Chan TL, Chan ASW, Zhao W, Chu KM, So S, Chen X, Yuen ST and Leung SY: Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005. View Article : Google Scholar : PubMed/NCBI
28	Shibata T, Kokubu A, Tsuta K and Hirohashi S: Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett. 283:203–211. 2009. View Article : Google Scholar : PubMed/NCBI
29	Farina Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, Kuppen PJ, Goossens-Beumer IJ, Lemmens VE, van de Velde CJ, et al: PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol. 34:523–531. 2011.PubMed/NCBI
30	Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, et al: Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat. 119:379–390. 2010. View Article : Google Scholar
31	Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM and Williams RL: Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 317:239–242. 2007. View Article : Google Scholar : PubMed/NCBI
32	Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, et al: Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 23:8774–8785. 2005. View Article : Google Scholar : PubMed/NCBI
33	Varlotto JM, Medford-Davis LN, Recht A, Flickinger JC, Schaefer E, Zander DS and DeCamp MM: Should large cell neuroendocrine lung carcinoma be classified and treated as a small-cell lung cancer or with other large cell carcinomas? J Thorac Oncol. 6:1050–1058. 2011. View Article : Google Scholar : PubMed/NCBI
34	Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S and Crinò L: Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol. 16:1041–1047. 2003. View Article : Google Scholar : PubMed/NCBI
35	Gustin JP, Cosgrove DP and Park BH: The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 8:733–740. 2008. View Article : Google Scholar : PubMed/NCBI
36	Pitt SC, Chen H and Kunnimalaiyaan M: Phosphatidylinositol 3-kinase-Akt signalling in pulmonary carcinoid cells. J Am Coll Surg. 209:82–88. 2009. View Article : Google Scholar : PubMed/NCBI